BioLamina AB

21 patents currently held · Updated Nov 14, 2026

2 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Sep 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 9, 2027
The maintenance fee for Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases (US 10,344,259) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
1 fee due Mar 26, 2027
The maintenance fee for Methods of producing RPE cells (US 11,767,509) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 10,829,733	Composition and method for enabling proliferation of pluripotent human stem cells In force Term ends Sep 2, 2028 · From the USPTO record	In force	Term ends Sep 2, 2028	From the USPTO record
US 8,951,799	Composition and method for enabling proliferation of pluripotent stem cells In force Ends no later than Feb 9, 2029 · Low confidence	In force	Ends no later than Feb 9, 2029	Low confidence
US 8,722,405	Composition and method for enabling proliferation of pluripotent stem cells In force Term ends Sep 12, 2029 · From the USPTO record	In force	Term ends Sep 12, 2029	From the USPTO record
US 8,415,156	Recombinant laminin-521 In force Ends no later than Dec 16, 2031 · From the USPTO record	In force	Ends no later than Dec 16, 2031	From the USPTO record
US 10,138,292	Cell culture medium In force Ends no later than Dec 16, 2031 · From the USPTO record	In force	Ends no later than Dec 16, 2031	From the USPTO record
US 9,534,038	Isolated laminin-421 In force Term ends Mar 1, 2032 · From the USPTO record	In force	Term ends Mar 1, 2032	From the USPTO record
US 9,499,794	Maintenance of differentiated cells with laminins In force Term ends Apr 19, 2033 · From the USPTO record	In force	Term ends Apr 19, 2033	From the USPTO record
US 12,391,915	Maintenance of differentiated cells with laminins In force Term ends May 23, 2033 · From the USPTO record	In force	Term ends May 23, 2033	From the USPTO record
US 11,155,781	Maintenance of differentiated cells with laminins In force Term ends Nov 16, 2033 · From the USPTO record	In force	Term ends Nov 16, 2033	From the USPTO record
US 10,889,801	Methods of producing RPE cells In force Term ends Dec 3, 2033 · From the USPTO record	In force	Term ends Dec 3, 2033	From the USPTO record

10 of 21 patents shown.

Pro members see all 21.

Pro members: see all 21 patents

Also on record, not counted in the 21: 2 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 no status recorded

List them